JP2001500486A5 - - Google Patents

Download PDF

Info

Publication number
JP2001500486A5
JP2001500486A5 JP1998511906A JP51190698A JP2001500486A5 JP 2001500486 A5 JP2001500486 A5 JP 2001500486A5 JP 1998511906 A JP1998511906 A JP 1998511906A JP 51190698 A JP51190698 A JP 51190698A JP 2001500486 A5 JP2001500486 A5 JP 2001500486A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998511906A
Other languages
English (en)
Other versions
JP2001500486A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/015155 external-priority patent/WO1998008546A2/en
Publication of JP2001500486A publication Critical patent/JP2001500486A/ja
Publication of JP2001500486A5 publication Critical patent/JP2001500486A5/ja
Ceased legal-status Critical Current

Links

Description

Figure 2001500486
Figure 2001500486
Figure 2001500486
Figure 2001500486
JP10511906A 1996-08-28 1997-08-28 Ｒａｒアンタゴニストとｒｘｒアゴニストとの治療学的組合せおよびその使用 Ceased JP2001500486A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2477296P 1996-08-28 1996-08-28
US60/024,772 1996-08-28
PCT/US1997/015155 WO1998008546A2 (en) 1996-08-28 1997-08-28 Therapeutic combinations of rar antagonists and rxr agonists and use thereof

Publications (2)

Publication Number Publication Date
JP2001500486A JP2001500486A (ja) 2001-01-16
JP2001500486A5 true JP2001500486A5 (ja) 2005-04-07

Family

ID=21822317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10511906A Ceased JP2001500486A (ja) 1996-08-28 1997-08-28 Ｒａｒアンタゴニストとｒｘｒアゴニストとの治療学的組合せおよびその使用

Country Status (11)

Country Link
US (2) US6130230A (ja)
EP (1) EP0928200B1 (ja)
JP (1) JP2001500486A (ja)
AT (1) ATE236654T1 (ja)
AU (1) AU731060B2 (ja)
CA (1) CA2263817A1 (ja)
DE (1) DE69720745T2 (ja)
ES (1) ES2196361T3 (ja)
IL (1) IL128723A0 (ja)
NO (1) NO990912L (ja)
WO (1) WO1998008546A2 (ja)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770896C (en) 1998-09-29 2006-09-07 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
CA2402413A1 (en) * 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
US20020090352A1 (en) * 2000-04-13 2002-07-11 Frederick Geissmann Compositions and methods for use in modulating immune system function
JP2004509608A (ja) * 2000-05-26 2004-04-02 ボード　オブ　トラスティーズ　オブ　ザ　ユニヴァースティ　オブ　イリノイ レチノイドにより調節される遺伝子の発現を同定する試薬及び方法
AU2001290816A1 (en) 2000-09-13 2002-03-26 Bristol-Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
EP1478384A2 (en) * 2001-06-11 2004-11-24 Ludwig Institute For Cancer Research Method for increasing the survival of dopamine secreting cells
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US20050112123A1 (en) * 2003-10-06 2005-05-26 Vaughan Michael R. Methods of treating proteinuria
GB2411115A (en) * 2004-02-19 2005-08-24 Medical Res Council Retinoic acid antagonists for the treatment of oesophageal disorders
WO2006030442A2 (en) 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP2181710A1 (en) * 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
EP2329817A1 (en) * 2009-09-04 2011-06-08 Ernst-Moritz-Arndt-Universität Greifswald Retinoic acid receptor antagonists, miR-10a inhibitors and inhibitors of HOXB1 or HOXB3 repressors for treating pancreatic cancer
CN103732231B (zh) 2011-06-24 2020-04-10 格里生物公司 炎性病症的预防和治疗
SG11201404608WA (en) 2012-02-13 2014-09-26 Gamida Cell Ltd Mesenchymal stem cells conditioned medium and methods of generating and using the same
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
EP4083029A1 (en) 2013-08-20 2022-11-02 University of Washington through its Center for Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydroxylase
EP4098257A1 (en) 2015-11-25 2022-12-07 IO Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
CN115671292A (zh) 2016-06-10 2023-02-03 Io治疗公司 用于癌症免疫疗法的受体选择性类视黄醇和rexinoid化合物和免疫调节剂
IL302133A (en) 2017-07-13 2023-06-01 Io Therapeutics Inc A combination of a rexinoid and retinoid substance with immunomodulatory properties and immunomodulatory substances for cancer treatment
AU2018326617B2 (en) 2017-08-31 2022-12-01 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
US20220031644A1 (en) * 2020-07-31 2022-02-03 The Trustees Of Columbia University In The City Of New York Method of treating adenoid cystic carcinoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2100582A1 (en) 1991-03-18 1992-09-19 David J. Mangelsdorf Response element compositions and assays employing same
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
JPH08504104A (ja) * 1993-05-18 1996-05-07 アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル レチノイン酸レセプター蛋白をコード化する遺伝子における改変を含む遺伝子工学的マウス
US5702914A (en) * 1994-12-21 1997-12-30 The Salk Institute For Biological Studies Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements
US5747661A (en) * 1995-01-13 1998-05-05 Howard Hughes Medical Institute Retinoid-inducible response elements
CA2210248A1 (en) 1995-01-13 1996-07-18 Ronald M. Evans Allosteric control of nuclear hormone receptors
US5559248A (en) * 1995-04-05 1996-09-24 Bristol-Myers Squibb Co. Retinoid-like heterocycles
US6025388A (en) * 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5906920A (en) 1995-08-29 1999-05-25 The Salk Institute For Biological Studies Methods for the detection of ligands for retinoid X receptors
EP1005344A4 (en) 1996-12-31 2003-03-19 Salk Inst For Biological Studi TREATMENT OF LIPOSARCOMAS WITH A COMBINATION OF THIAZOLIDINEDIONS AND SELECTIVE RETINOID-X RECEPTOR AGONISTS
WO1998029113A1 (en) 1996-12-31 1998-07-09 The Salk Institute For Biological Studies Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds

Similar Documents

Publication Publication Date Title
JP2000503556A5 (ja)
JP2001521373A5 (ja)
JP2000500076A5 (ja)
JP2000507577A5 (ja)
JP2000509021A5 (ja)
JP2000508849A5 (ja)
JP2000500055A5 (ja)
JP2000512140A5 (ja)
JP2000500026A5 (ja)
JP2000502472A5 (ja)
JP2001502854A5 (ja)
JP2000517136A5 (ja)
JP2001507517A5 (ja)
JP2000502485A5 (ja)
JP2000516201A5 (ja)
JP2000502425A5 (ja)
JP2000501774A5 (ja)
JP2000502570A5 (ja)
JP2000502568A5 (ja)
JP2001500486A5 (ja)
JP2000502316A5 (ja)
JP2000502714A5 (ja)
JP2000505297A5 (ja)
JP2000504731A5 (ja)
JP2000500318A5 (ja)